Innate Pharma

Innate Pharma Revenue

The The revenue of Innate Pharma (IPH.PA) as of Nov 20, 2026 is 2.79 M EUR. In the previous year, The revenue was 12.62 M EUR — a change of -77.92% (lower).

Revenue

2.79 MEUR

YoY

-77.92%

Last updated:

In 2025, Innate Pharma's sales reached 2.79 M EUR, a -77.92% difference from the 12.62 M EUR sales recorded in the previous year.

Revenue at Innate Pharma has contracted by 4.1% per year over the past 19 years to 2.79 M EUR.

The Innate Pharma Revenue history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
Date
Revenue
Jan 1, 2023
51.90 M EUR
Jan 1, 2024
12.62 M EUR
Jan 1, 2025
2.79 M EUR
Jan 1, 2026 (e)
47.48 M EUR
Jan 1, 2027 (e)
89.32 M EUR
Jan 1, 2028 (e)
111.14 M EUR
Jan 1, 2029 (e)
60.03 M EUR
Jan 1, 2030 (e)
146.34 M EUR
The Innate Pharma Revenue history
YEARRevenueYoY
est146.34 MEUR+143.78%
est60.03 MEUR-45.99%
est111.14 MEUR+24.44%
est89.32 MEUR+88.11%
est47.48 MEUR+1,603.61%
2.79 MEUR-77.92%
12.62 MEUR-75.68%
51.90 MEUR+4.56%
49.64 MEUR+309.83%
12.11 MEUR-82.64%
69.77 MEUR+1.16%
68.97 MEUR-13.67%
79.89 MEUR+144.83%
32.63 MEUR-41.90%
56.16 MEUR+213.64%
17.91 MEUR+1,874.20%
907,000.00EUR-92.73%
12.47 MEUR+20.16%
10.38 MEUR-11.61%
11.74 MEUR+171.76%
4.32 MEUR-44.01%
7.72 MEUR-40.30%
12.92 MEUR-9.56%
14.29 MEUR+130.67%
6.20 MEUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Innate Pharma Revenue

Innate Pharma Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
51.90 M EUR
-12.67 M EUR
-7.57 M EUR
Jan 1, 2024
12.62 M EUR
-51.58 M EUR
-49.47 M EUR
Jan 1, 2025
2.79 M EUR
-57.36 M EUR
-49.18 M EUR
Jan 1, 2026 (e)
47.48 M EUR
1.30 M EUR
18.64 M EUR
Jan 1, 2027 (e)
89.32 M EUR
-11.88 M EUR
73.35 M EUR
Jan 1, 2028 (e)
111.14 M EUR
71.25 M EUR
34.04 M EUR
Jan 1, 2029 (e)
60.03 M EUR
128,417.00 EUR
-2.22 M EUR
Jan 1, 2030 (e)
146.34 M EUR
62.56 M EUR
42.96 M EUR

Innate Pharma Margins

Innate Pharma stock margins

The Innate Pharma margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Innate Pharma. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Innate Pharma.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2023
10.83 %
-24.41 %
-14.59 %
Jan 1, 2024
-252.41 %
-408.61 %
-391.94 %
Jan 1, 2025
100.00 %
-2,058.02 %
-1,764.51 %
Jan 1, 2026 (e)
100.00 %
2.74 %
39.26 %
Jan 1, 2027 (e)
100.00 %
-13.30 %
82.13 %
Jan 1, 2028 (e)
100.00 %
64.10 %
30.63 %
Jan 1, 2029 (e)
100.00 %
0.21 %
-3.70 %
Jan 1, 2030 (e)
100.00 %
42.75 %
29.35 %

Innate Pharma Stock analysis

What does Innate Pharma do? The company Innate Pharma SA is a biotechnology company that was founded in 1999 by immunologist Hervé Brailly. The company is headquartered in Marseille, France, and currently employs approximately 200 people. The business model of Innate Pharma is based on the research and development of immunotherapeutic drugs for various types of cancer and infectious diseases. The company leverages its expertise in the research and utilization of the so-called "innate immune system," which refers to the body's natural defense mechanisms against pathogens and cancer cells. Innate Pharma is active in various business sectors focusing on the development and marketing of therapeutic agents and products. These include: - Oncology: In the field of oncology, the company focuses on the development of drugs that specifically target cancer cells and inhibit cancer growth. Innate Pharma particularly emphasizes the research of antibodies that bind specifically to cancer cells and destroy them. An important product in this area is the medication Lumoxiti, used for the treatment of hairy cell leukemia. - Infectious diseases: In addition to cancer research, Innate Pharma also dedicates itself to the development of therapeutic agents against various infectious diseases. A significant focus here is on viral infections such as COVID-19. The company collaborates closely with various partners and research institutions to identify and develop promising agents. - Autoimmune diseases: Another business sector of Innate Pharma is the research and development of therapies for autoimmune diseases. The company primarily focuses on the use of antibodies and other proteins that aim to selectively influence the immune system and prevent misguided reactions of the body. Innate Pharma has developed and launched a variety of products in recent years. These primarily include therapeutic antibodies that specifically target various structures in the body and activate the body's immune defenses. An important product in this area is the monoclonal antibody IPH4102, used for the treatment of T-cell lymphoma. Innate Pharma collaborates closely with various partners and research institutions to identify and develop promising agents. These include large pharmaceutical companies such as Roche and Bristol-Myers Squibb, as well as innovative start-ups and university hospitals. The close collaboration with the research community aims to ensure that Innate Pharma remains at the forefront of progress and can quickly implement new developments. Like many biotechnology companies, research and development at Innate Pharma are very costly. To finance the development of new therapies, the company relies on cooperation with investors and the issuance of shares. In 2019, Innate Pharma generated a revenue of approximately 47 million euros and incurred a loss of about 55 million euros. However, the company is optimistic about achieving further successes in the coming years and expanding its position as a leading biotechnology company. Innate Pharma is one of the most popular companies on Eulerpool.

Revenue Details

Understanding Innate Pharma's Sales Figures

The sales figures of Innate Pharma originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Innate Pharma’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Innate Pharma's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Innate Pharma’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Innate Pharma stock

The revenue of Innate Pharma is 2.79 M EUR in 2025.

The revenue of Innate Pharma changed from 12.62 M EUR to 2.79 M EUR, representing a -77.92% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The revenue Innate Pharma since 2006 – with annual values, charts, and detailed analysis.

Revenue is the total value of all goods sold in a period. It is calculated by multiplying the quantity of each product sold by its selling price. Revenue does not include any costs (material costs, personnel costs, etc.), whereas net proceeds only deduct revenue reductions associated with the sale (discounts, etc.).

The revenue's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The revenue's Innate Pharma historically and in real time.

The revenue in assessing a stock

Revenue is an important financial measure used in the valuation of stocks. It is a measure of a company's economic activity and can serve as an indicator of the company's success. Revenue is considered one of the most important factors in stock valuation. In addition, revenue can also be used to calculate other financial measures such as earnings per share and price-earnings ratio.

History and utilization of revenue

Revenue has long been considered one of the most important financial indicators. It was used in the 19th century as one of the first financial indicators to measure a company's economic activity. Since then, revenue has been regularly used to evaluate companies.

Revenue is usually calculated as a percentage of the company's equity. It can also be used to determine the overall profitability of a company. There are many different types of revenue that can be used to measure a company's economic activity, such as gross revenue, net revenue, and revenue from international business.

The revenue can also be used to evaluate stocks. For example, the revenue of a company can be used to evaluate the success of the company. If a company has high revenue, it means that it is a profitable company because it has high demand for its products or services.

Calculation and Application of Revenue

In order to calculate a company's revenue, the company's income must be deducted from its expenses. The income can come from various sources, such as sales, licensing fees, services, etc. The expenses can include costs for production, procurement, inventory, sales, and administration.

The revenue can then be used to calculate various financial ratios. For example, the revenue can be used to calculate the price-earnings ratio (P/E ratio) of a company. This is a measure of a company's profitability, calculated by taking the ratio of the stock price to earnings per share.

Revenue can also be used to calculate earnings per share (EPS) of a company. This is a measure of a company's profit per share. EPS is calculated by dividing earnings by the number of shares issued.

Use of revenue by investors

Investors use revenue to evaluate stocks, as revenue is an indicator of a company's success. For example, an investor can compare a company's revenue to see how successful it is. An investor can also use a company's revenue to calculate its price-to-earnings ratio and earnings per share.

An example: An investor looks at a company that has a revenue of 25 million euros. He compares this revenue to that of the competitor, which has a revenue of 35 million euros. The investor can then see that the company with 25 million euros in revenue is less successful than the company with 35 million euros in revenue.

Advantages and Disadvantages of Revenue.

Revenue is a very useful tool for valuing stocks as it measures a company's economic activity. Revenue can also be used to calculate other financial ratios such as the price-earnings ratio and earnings per share.

However, one disadvantage is that revenue alone is not a meaningful indicator of a company's success. It is important to consider revenue in comparison to other financial metrics such as earnings per share and price-to-earnings ratio to get a complete picture of the company.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Innate Pharma

All Key Metrics — Innate Pharma